Dupilumab (Dupixent)
Fully human IgG4 monoclonal antibody targeting IL-4 receptor alpha, blocking IL-4 and IL-13 signaling. Approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, EoE, and prurigo nodularis. Typical 300 mg SC every 2 weeks after loading. Exhibits target-mediated drug disposition with biphasic clearance. Well tolerated; most common AE is injection-site reaction and conjunctivitis.
Projected serum levels — 300 mg, custom (shown daily)
Maintenance schedule: 300 mg custom (shown daily) (subcutaneous).
Loading schedule: 900 mg on day 1, then 300 mg custom (shown daily) — reaching therapeutic levels sooner.
Modeled steady state after ~4 days: peak ≈ 293 mg, trough ≈ 293 mg body load. Population-based estimate over 15 days for a 300 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Biologic
- Route modeled
- Subcutaneous
- Model confidence
- inferred
- Common dose
- 300 mg
- Suggested maximum
- 600 mg/day
- Reference dose range
- 150–600 mg (single dose)
- Suggested cadence
- custom (shown daily)
- Validated against
- 600 mg sc — Cmax 70 mg/L at 168 h
Research behind this entry
-
Clinical pharmacokinetics and pharmacodynamics of dupilumab
Population PK analysis quantifying dupilumab's target-mediated disposition, nonlinear clearance at low concentrations, and typical exposure at 300 mg Q2W.
-
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis (SOLO 1 and SOLO 2)
Pivotal SOLO 1/2 trials demonstrating dupilumab efficacy in moderate-to-severe atopic dermatitis, leading to first biologic approval in the indication.
2 published studies referenced in the app, each with a plain-language summary.